Boston Scientific Q3 2026 sales rise 1.5%, Q4 revenue guided lower

what happened

According to TradingView, Boston Scientific reported third-quarter 2026 revenue of $5.138 billion, up 1.5% from a year earlier. Adjusted earnings per share came in at $0.73, down from $0.75, while GAAP earnings per share fell to $0.40 from $0.51.

By segment, Cardiovascular sales rose 1.9% and MedSurg grew 0.6%. Europe, the Middle East and Africa gained 6.1% on an operational basis and Latin America and Canada rose 10.5%, while the United States edged up 0.5% and Asia-Pacific slipped 1.1%.

For full-year 2026, the company now expects sales growth of about 4.25% on a reported basis and roughly 3.75% organically, with adjusted EPS of $3.16 to $3.18. It forecasts fourth-quarter sales to fall between 3.0% and 1.0%, with adjusted EPS of $0.77 to $0.79.

why it matters

Management described the year as challenging, citing the cybersecurity incident and the effort to restore operations. For investors the key figure is the fourth-quarter outlook, since a projected sales decline would mark a slowdown after the third-quarter gain. The report matters mainly for Boston Scientific shares and the medical device sector.

market impact

Boston Scientific shares: a projected fourth-quarter sales decline weighs on the stock

• ▼Boston Scientific shares pressure down — fourth-quarter sales guidance points to a decline after third-quarter growth

tags

instruments